BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22284136)

  • 21. Health-related quality-of-life assessment in dermatologic practice: relevance and application.
    van Cranenburgh OD; Prinsen CA; Sprangers MA; Spuls PI; de Korte J
    Dermatol Clin; 2012 Apr; 30(2):323-32, x. PubMed ID: 22284146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Willingness-to-pay and quality of life in patients with vitiligo.
    Radtke MA; Schäfer I; Gajur A; Langenbruch A; Augustin M
    Br J Dermatol; 2009 Jul; 161(1):134-9. PubMed ID: 19298268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrepancies between the Dermatology Life Quality Index and utility scores.
    Rencz F; Baji P; Gulácsi L; Kárpáti S; Péntek M; Poór AK; Brodszky V
    Qual Life Res; 2016 Jul; 25(7):1687-96. PubMed ID: 26684848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health related utility measurement: an introduction.
    Bakker C; van der Linden S
    J Rheumatol; 1995 Jun; 22(6):1197-9. PubMed ID: 7674256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient preferences for depression treatment programs and willingness to pay for treatment.
    Morey E; Thacher JA; Craighead WE
    J Ment Health Policy Econ; 2007 Jun; 10(2):73-85. PubMed ID: 17603148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A utility-theoretic model for QALYs and willingness to pay.
    Klose T
    Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acceptance and understandability of various methods of health valuations for the chronically ill: willingness to pay, visual analogue scale and rating scale].
    Meder M; Farin E
    Gesundheitswesen; 2009 Nov; 71(11):e62-71. PubMed ID: 20094981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Willingness to pay and quality of life in patients with pruritic skin disorders.
    Stefanidou M; Evangelou G; Kontodimopoulos N; Koumaki D; Krueger-Krasagakis SE; Yosipovitch G; Krasagakis K
    Arch Dermatol Res; 2019 Apr; 311(3):221-230. PubMed ID: 30788568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Willingness-to-pay utility assessment: feasibility of use in normative patient decision support systems.
    Flowers CR; Garber AM; Bergen MR; Lenert LA
    Proc AMIA Annu Fall Symp; 1997; ():223-7. PubMed ID: 9357621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance of skin disease as assessed by "willingness-to-pay".
    Parks L; Balkrishnan R; Hamel-Gariépy L; Feldman SR
    J Cutan Med Surg; 2003; 7(5):369-71. PubMed ID: 14505193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
    Byrne MM; O'malley K; Suarez-Almazor ME
    Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility measures of health-related quality of life in patients treated for benign paroxysmal positional vertigo.
    Roberts RA; Abrams H; Sembach MK; Lister JJ; Gans RE; Chisolm TH
    Ear Hear; 2009 Jun; 30(3):369-76. PubMed ID: 19322083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preference-based quality of life measures in people with visual impairment.
    Kymes SM; Lee BS
    Optom Vis Sci; 2007 Aug; 84(8):809-16. PubMed ID: 17700344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A community-based study of acne-related health preferences in adolescents.
    Chen CL; Kuppermann M; Caughey AB; Zane LT
    Arch Dermatol; 2008 Aug; 144(8):988-94. PubMed ID: 18711070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
    King JT; Tsevat J; Lave JR; Roberts MS
    Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Burden of skin disease.
    Smith JG
    J Am Acad Dermatol; 2007 Apr; 56(4):706. PubMed ID: 17367624
    [No Abstract]   [Full Text] [Related]  

  • 37. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP?
    Van Houtven G; Powers J; Jessup A; Yang JC
    Health Econ; 2006 Aug; 15(8):775-95. PubMed ID: 16544361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is the Dermatology Life Quality Index really time-sensitive?
    Esmann S; Jemec GB
    J Eur Acad Dermatol Venereol; 2010 May; 24(5):621-2. PubMed ID: 19929934
    [No Abstract]   [Full Text] [Related]  

  • 39. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology.
    Bickers DR; Lim HW; Margolis D; Weinstock MA; Goodman C; Faulkner E; Gould C; Gemmen E; Dall T; ;
    J Am Acad Dermatol; 2006 Sep; 55(3):490-500. PubMed ID: 16908356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of willingness to pay to study values for pharmacotherapies for migraine headache.
    Lenert LA
    Med Care; 2003 Feb; 41(2):299-308. PubMed ID: 12555057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.